Drugs / Duvalisib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06151106 | Nov 2023 → Dec 2026 expected | non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duvalisib | “Chidamide and Duvalisib” NCT06151106 ↗ |